TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16132805
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of hormone replacement therapy (HRT) in women with BMI<30
Study: 16132805
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of hormone replacement therapy (HRT) in women who regularly use aspirin or ibuprofen
Study: 7049817
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg 3 times daily
Study: 31821350
Drug: brief group-delivered
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: brief group-delivered cognitive-behavioral therapy (bCBT)
Study: 23820061
Drug: Experimental arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm (treatment)
Study: 19362552
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg/d for 8 weeks followed by 4 weeks of placebo
Study: 17699390
Drug: AA (Nutrineal
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA (Nutrineal 1.1%) plus G (Physioneal 1.36 to 3.86%)
Study: 15126525
Drug: AndroGel (T
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroGel (T gel) 1% CIII, 5, 7.5, or 10 g per day for up to 42 months
Study: 11483282
Drug: 2.5 microg
Normalized name: Digoxin 62.5 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 microg recombinant HB vaccine
Study: 11483282
Drug: 5 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg recombinant HB vaccine
Study: 11483282
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg recombinant HB vaccine
Study: 2590612
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg daily for 12 days
Study: 2590612
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg daily for 12 days with ranitidine 150 mg 30 min before aspirin
Study: 2590612
Drug: Control values
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control values (no aspirin)
Study: 21401949
Drug: Acetaminophen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4 g/day) for 10 days in non-drinkers (Trial 1)
Study: 21401949
Drug: Acetaminophen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4 g/day) for 10 days in moderate drinkers (Trial 2)
Study: 21401949
Drug: Acetaminophen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4 g/day) for 5 days in chronic alcohol abusers (Trial 3)
Study: 21401949
Drug: Acetaminophen overdose
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen overdose (acute ingestion)
Study: 21401949
Drug: Non-acetaminophen hepatotoxin
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-acetaminophen hepatotoxin exposure
Study: 17436826
Drug: ER-minocycline 1
Normalized name: meclocycline
DrugBank: Meclocycline (DB13092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ER-minocycline 1 mg/kg daily
Study: 12854893
Drug: Intrathecal (IT)
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal (IT) chemotherapy via lumbar puncture (LP) for prophylaxis
Study: 12854893
Drug: Intrathecal (IT)
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal (IT) chemotherapy via lumbar puncture (LP) for treatment
Study: 12854893
Drug: Systemic agents
Normalized name: ANTIACNE AGENTS,SYSTEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic agents that cross the blood-brain barrier for prophylaxis
Study: 12854893
Drug: Systemic agents
Normalized name: ANTIACNE AGENTS,SYSTEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic agents that cross the blood-brain barrier for treatment
Study: 16229368
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment method
Study: 12201326
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg ethinylestradiol (EE) + 100 μg levonorgestrel (LNG)
Study: 10030555
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin 0.1% solution
Study: 10030555
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone phosphate 0.1% solution
Study: 7010995
Drug: Somatropin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatropin (0.1 IU/kg in three doses per week)
Study: 7010995
Drug: Somatropin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatropin (0.1 IU/kg in three doses per week) + Oxandrolone (0.1 mg/kg/day)
Study: 31435774
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg three times daily initially (900 mg), with 300 mg weekly incremental dose till pain was controlled, maximum daily dose of 2700 mg
Study: 28323503
Drug: ALO 25
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO 25 mg QD
Study: 28323503
Drug: ALO 25
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO 25 mg QD and PIO 30 mg QD
Study: 23472765
Drug: Trophic enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trophic enteral feedings (15 mL/kg/d) during indomethacin or ibuprofen treatment (n = 81)
Study: 23472765
Drug: No feeds
Approvals — FDA: no, EMA: no, PMDA: no
Description: No feeds (fasting [nil per os] group) during indomethacin or ibuprofen treatment (n = 96)
Study: 21214369
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy (LILT) using a 630 nm diode laser
Study: 21214369
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (Dexamethason mouth wash)
Study: 19391533
Drug: Pecking moxibustion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pecking moxibustion therapy
Study: 11262983
Drug: Nimesulide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (1.5 mg/kg/dose)
Study: 11262983
Drug: Paracetamol (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (10.0 mg/kg/dose)
Study: 11262983
Drug: Ibuprofen-paracetamol combination
Normalized name: ibuprofen, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-paracetamol combination (10.0 mg/kg/dose)
Study: 8392581
Drug: High power
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High power density (HPD) laser treatment (60 W, spot size 1-1.5 mm)
Study: 8392581
Drug: Low power
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low power density (LPD) laser treatment (20 W, spot size 1-1.5 mm)
Study: 3549473
Drug: sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 1 g qid
Study: 3549473
Drug: NSAIDs continued
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs continued during treatment
Study: 3549473
Drug: NSAIDs stopped
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs stopped during treatment
Study: 30587217
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard treatment
Study: 19955694
Drug: Class Ia
Normalized name: Antiarrhythmics, class Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class Ia antiarrhythmic agents
Study: 19955694
Drug: Class Ib
Normalized name: Antiarrhythmics, class Ib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class Ib antiarrhythmic agents
Study: 19955694
Drug: Class Ic
Normalized name: Antiarrhythmics, class Ic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class Ic antiarrhythmic agents
Study: 19955694
Drug: Class III
Normalized name: HLA class III antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class III antiarrhythmic agents
Study: 18398154
Drug: bexarotene 400
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bexarotene 400 mg/m(2)/d with cisplatin/vinorelbine
Study: 15125904
Drug: Montelukast (Singulair)
Normalized name: montelukast Chewable Tablet [Singulair]
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (Singulair) 10 mg daily for two menstrual cycles
Study: 15125904
Drug: Ibuprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200 mg tablets) as needed
Study: 11515643
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health care education (OHCE) for nursing home caregivers
Study: 9763500
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A-hepatitis B vaccine administered at 0, 1, and 6 months
Study: 28631050
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion rate titrated to keep ANI monitoring values between 50–70 (Group ANI, n: 22)
Study: 28631050
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion rate regulated according to hemodynamic parameters (Group control, n: 22)
Study: 28475555
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine with 2 μg/ml fentanyl
Study: 28475555
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine with 2 μg/ml neostigmine
Study: 28475555
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine with 4 μg/ml neostigmine
Study: 28475555
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine with 8 μg/ml neostigmine
Study: 21364505
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with 2.5 ng mL(‐1) of remifentanil (low‐remifentanil group)
Study: 21364505
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with 5.0 ng mL(‐1) of remifentanil (high‐remifentanil group)
Study: 16488434
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine continuous infusion for 120 hours
Study: 16488434
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution continuous infusion for 120 hours
Study: 3530032
Drug: Sustained-release terbutaline
Normalized name: terbutaline Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release terbutaline 7.5 mg
Study: 28737261
Drug: Integrative cognitive‐behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative cognitive‐behavioural therapy for PGD (PG‐CBT)
Study: 27707827
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg daily for 2 years)
Study: 22856254
Drug: Wool underwear
Normalized name: sheep wool preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wool underwear (treatment group)
Study: 21189769
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium hypochlorite gel
Study: 15955465
Drug: Step‐One‐Diet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step‐One‐Diet plus glucomannan in gelatine capsules
Study: 1910798
Drug: Ephedrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (10 mg IV bolus injections)
Study: 1910798
Drug: Phenylephrine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (80 microgram IV bolus injections)
Study: 31887309
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg + metformin 1700 mg daily + lifestyle
Study: 31887309
Drug: metformin 1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 1700 mg daily + lifestyle
Study: 29112512
Drug: Antibiotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic administration postincision
Study: 29112512
Drug: Antibiotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic administration preincision
Study: 29112512
Drug: Nonadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadministration of antibiotics
Study: 29112512
Drug: Antibiotics provided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics provided before incision
Study: 22452536
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml reciprocating procedure device (RPD) mechanical syringe
Study: 22452536
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml vacuum syringe
Study: 19890774
Drug: Venlafaxine extended
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended release (dosage not specified)
Study: 18260957
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg o.d.)
Study: 18260957
Drug: Fluvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (80 mg o.d.)
Study: 18260957
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Valsartan and Fluvastatin
Study: 15821899
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity pulsed ultrasound therapy for 20 min daily for 6 weeks
Study: 15821899
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity pulsed ultrasound therapy
Study: 1359139
Drug: Captopril treatment
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril treatment (mean daily dose 69.1 mg)
Study: 3913160
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy (tamoxifen, fluorouracil, vincristine, methotrexate, cyclophosphamide, mitoxantrone)
Study: 26920994
Drug: 4 ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ± 1 calendar days of antibiotics
Study: 26920994
Drug: Maximum of
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum of 10 calendar days of therapy
Study: 22723577
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure therapy (systolic <120 mmHg)
Study: 22723577
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure therapy (systolic <140 mmHg)
Study: 10392325
Drug: Bosentan 100
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 100 mg
Study: 10392325
Drug: Bosentan 200
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 200 mg
Study: 10392325
Drug: Bosentan 500
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 500 mg
Study: 10392325
Drug: Bosentan 1000
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 1000 mg
Study: 10392325
Drug: Bosentan 500
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 500 mg (with additional IV doses)
Study: 10392325
Drug: Bosentan (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (doses above 500 mg)
Study: 10392325
Drug: Bosentan (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (oral treatment phase)
Study: 8922245
Drug: Anthracycline-containing single,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-containing single, alternating or 'hybrid' combination chemotherapy regimens
Study: 8922245
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality regimens with chemotherapy and radiation therapy
Study: 1858176
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg indometacin
Study: 1858176
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment with 250 mg naproxen b.i.d.
Study: 29551226
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of quadrivalent HPV vaccine (Gardasil™)
Study: 29551226
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of quadrivalent HPV vaccine (Gardasil™)
Study: 29551226
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of quadrivalent HPV vaccine (Gardasil™)
Study: 19922703
Drug: Topical hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydrocortisone
Study: 10624823
Drug: Scopolamine hydrobromide,
Normalized name: Scopolamine Hydrobromide, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine hydrobromide, 0.3 mg, i.v.
Study: 10624823
Drug: Glycopyrrolate, 0.2
Normalized name: Glycopyrrolate, 0.2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate, 0.2 mg, i.v.
Study: 8538922
Drug: Isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 10 mg daily for 1 week
Study: 1934868
Drug: Folate supplementation
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate supplementation (1 mg/day) during methotrexate therapy
Study: 30734207
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg subcutaneously every 2 weeks (Q2W), with dose increase to 150 mg Q2W at week 12 if LDL-C was >= 70 mg/dl
Study: 26259809
Drug: RSV F
Normalized name: Respiratory syncytial virus fusion protein.
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV F vaccine (60 or 90 µg) with or without aluminum phosphate adjuvant, 1 or 2 doses
Study: 24101715
Drug: Immediate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate therapy group using the 'Exploring Feelings' manual (Attwood, 2004) for seven weekly sessions.
Study: 24101715
Drug: Delayed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed therapy group (control).
Study: 22436198
Drug: Acyclovir (herpes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (herpes simplex virus-suppressive therapy)
Study: 19473149
Drug: Vibration stimulus
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration stimulus during local anaesthetic injections
Study: 19473149
Drug: No vibration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vibration stimulus during local anaesthetic injections
Study: 19473149
Drug: Infiltration anaesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration anaesthetic injection with vibration
Study: 19473149
Drug: Block anaesthetic
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Block anaesthetic injection with vibration
Study: 16980070
Drug: Anti-IL-2R monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-IL-2R monoclonal antibody (n = 50)
Study: 11200745
Drug: Opiate abusers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate abusers (group II) after treatment
Study: 11200745
Drug: Opiate abusers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate abusers (group II) before and after treatment
Study: 11200745
Drug: Alcohol abusers
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol abusers (group I) before treatment
Study: 6487441
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 4 ml in 8% glucose
Study: 6487441
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 4 ml in 5% glucose
Study: 6487441
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 4 ml in 0% glucose (glucose-free solution)
Study: 6487441
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 4 ml in hyperbaric solutions (8% and 5% glucose)
Study: 31113718
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood sampling (5 mL from the placental end of the umbilical cord)
Study: 26237827
Drug: Combined Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Traditional Chinese Medicine (TCM) therapy including shenfu injection (60 mL) and deproteinized calf blood injection (DCBI) (1.2 g) for Yang-Qi deficiency; shenmai injection (60 mL) and DCBI (1.2 g) for Yin-Qi deficiency, once daily for 21 days.
Study: 26237827
Drug: Aricept (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aricept (5 mg, once daily)
Study: 19845435
Drug: bifendate (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: bifendate (three times daily for 14 days)
Study: 2647124
Drug: Short contact
Normalized name: BenzePrO Short Contact 9.8 % Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short contact dithranol in stiff emulsifying ointment base
Study: 2647124
Drug: Stiff emulsifying
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stiff emulsifying ointment
Study: 29767639
Drug: Tenofovir (TFV)
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir (TFV) reduced-glycerin 1% gel applied vaginally for 14 days
Study: 29767639
Drug: Tenofovir (TFV)
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir (TFV) reduced-glycerin 1% gel applied rectally for 14 days
Study: 29767639
Drug: Cervicovaginal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervicovaginal lavage fluid and rectal fluid collected 24 hours after dosing
Study: 28098723
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (ERM and ILM removal)
Study: 26525473
Drug: Physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological solution (group 1)
Study: 26525473
Drug: 0.05% xylometazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% xylometazoline solution (group 2)